A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This multicenter, open-label, dose-escalating study will assess the safety and efficacy of
DFRF4539A in patients with relapsed or refractory multiple myeloma. Cohorts of patients will
receive multiple ascending doses of intravenous DFRF4539A every 3 weeks or weekly. Patients
exhibiting acceptable safety and evidence of clinical benefit may receive DFRF4539A for up to
17 cycles. Anticipated time on study treatment is 1 year or until disease progression or
unacceptable toxicity occurs.